Skip to main content
. 2015 Feb;77(1-2):7–17.

Fig. 2.

Fig. 2

Structure and inhibitory activity of FLT3 inhibitors.

Tandutinib, Lestaurtinib and Midostaurin are first-generation FLT3 inhibitors. The second-generation FLT3 inhibitors, Sorafenib and Quizartinib, show clinical efficacy, while several problems regarding adverse effects and resistant mutations should be resolved before clinical use. Crenolanib is a recently developed FLT3 inhibitor, which is potent against both FLT3-ITD and FLT3-KDM.